Clinical Research Directory
Browse clinical research sites, groups, and studies.
Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis
Sponsor: Mercy Medical Center
Summary
Investigators want to compare the seroconversion rates between two-dose and three-dose regimens of the hepatitis B vaccine (Heplisav B) among patients with cirrhosis, a randomized prospective study.
Official title: Comparison the Seroconversion Rate Between Two-dose and Three-dose Regimens of Heplisav B Among Patients With Cirrhosis, a Randomized-control Prospective Study.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
200
Start Date
2020-09-14
Completion Date
2028-12-01
Last Updated
2024-11-19
Healthy Volunteers
No
Interventions
Heplisav-B Injectable Product, 2-dose regimen
Investigators will randomly assign patients into a 2-dose regimen.
Heplisav-B Injectable Product, 3-dose regimen
Investigators will randomly assign patients into a 3-dose regimen.
Locations (1)
Mercy Medical Center
Baltimore, Maryland, United States